Twist Bioscience ( (TWST) ) has released its Q1 earnings. Here is a breakdown of the information Twist Bioscience presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Twist Bioscience is a synthetic biology and genomics company that leverages a disruptive DNA synthesis platform to produce a range of synthetic DNA-based products for various industries, including healthcare, industrial chemicals, and agriculture.
Twist Bioscience has reported record revenue for the first quarter of fiscal 2025, marking an impressive eighth consecutive quarter of growth. The company achieved a total revenue of $88.7 million, which represents a 24% increase compared to the same period last year.
Key financial highlights include a significant improvement in gross margin, which rose to 48.3% from 40.5% year-over-year. The company’s SynBio and NGS segments showed strong performance, with revenues growing by 28% and 23%, respectively. Despite a net loss of $31.6 million, Twist Bioscience recorded an improved adjusted EBITDA of $(16.3) million, down from $(27.8) million in the previous year.
Looking ahead, Twist Bioscience anticipates continued growth, forecasting total revenue for the fiscal year 2025 to be between $372 million and $379 million. The company expects its gross margin to exceed 50% by the fourth quarter, as it remains focused on achieving adjusted EBITDA breakeven and driving sustainable growth in the future.
